A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

Maj Schneider Thomsen; Torben Moos

doi:10.1016/j.medj.2022.11.006

A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain

Med. 2022 Dec 9;3(12):815-817. doi: 10.1016/j.medj.2022.11.006.

Authors

Maj Schneider Thomsen¹, Torben Moos²

Affiliations

¹ Neurobiology Research and Drug Delivery, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
² Neurobiology Research and Drug Delivery, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark. Electronic address: [email protected].

PMID: 36495860
DOI: 10.1016/j.medj.2022.11.006

Abstract

The use of therapeutic antibodies for treating diseases in the CNS is hampered by the blood-brain barrier (BBB). In this issue, Edavettal et al.¹ report on a novel bioengineered antibody not only capable of passing the BBB but also for intervening in pathological protein deposition and subsequent induction of clearing by microglia.

Publication types

Comment

MeSH terms

Antibodies, Bispecific* / therapeutic use
Biological Transport
Blood-Brain Barrier* / metabolism
Brain / metabolism

Substances

Antibodies, Bispecific